Endothelin receptor antagonists

Details Endothelin receptor antagonists Endothelin receptor antagonists

1995-06-07

1998-11-10

Grumbling, Matthew V.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

514258, 544280, 544350, A61K 31505, C07D23900

Patent

active

058344691

DESCRIPTION:

BRIEF SUMMARY
FIELD OF THE INVENTION

The present invention relates to novel pyrrolopyrizine and pyrrolopyrimidine derivatives, pharmaceutical compositions containing these compounds and their use as endothelin receptor antagonists.
Endothelin (ET) is a highly potent vasoconstrictor peptide synthesized and released by the vascular endothelium. Endothelin exists as three isoforms, or all of the isoforms of endothelin!. Endothelin has profound effects on the cardiovascular system, and in particular, the coronary, renal and cerebral circulation. Elevated or abnormal release of endothelin is associated with smooth muscle contraction which is involved in the pathogenesis of cardiovascular, cerebrovascular, respiratory and renal pathophysiology. Elevated levels of endothelin have been reported in plasma from patients with essential hypertension, acute myocardial infarction, subarachnoid hemorrhage, atherosclerosis, and patients with uraemia undergoing dialysis.
In vivo, endothelin has pronounced effects on blood pressure and cardiac output. An intravenous bolus injection of ET (0.1 to 3 nmol/kg) in rats causes a transient, dose-related depressor response (lasting 0.5 to 2 minutes) followed by a sustained, dose-dependent rise in arterial blood pressure which can remain elevated for 2 to 3 hours following dosing. Doses above 3 nmol/kg in a rat often prove fatal.
Endothelin appears to produce a preferential effect in the renal vascular bed. It produces a marked, long-lasting decrease in renal blood flow, accompanied by a significant decrease in GFR, urine volume, urinary sodium and potassium excretion. Endothelin produces a sustained antinatriuretic effect, despite significant elevations in atrial natriuretic peptide. Endothelin also stimulates plasma renin activity. These findings suggest that ET is involved in the regulation of renal function and is involved in a variety of renal disorders including acute renal failure, cyclosporine nephrotoxicity, radio contrast induced renal failure and chronic renal failure.
Studies have shown that in vivo, the cerebral vasculature is highly sensitive to both the vasodilator and vasoconstrictor effects of endothelin. Therefore, ET may be an important mediator of cerebral vasospasm, a frequent and often fatal consequence of subarachnoid hemorrhage.
ET also exhibits direct central nervous system effects such as severe apnea and ischemic lesions which suggests that ET may contribute to the development of cerebral infarcts and neuronal death.
ET has also been implicated in myocardial ischemia (Nichols et al. Br. J. Pharm. 99: 597-601, 1989 and Clozel and Clozel, Circ. Res., 65: 1193-1200, 1989) coronary vasospasm (Fukuda et al., Eur. J. Pharm. 165: 301-304, 1989 and Luscher, Circ. 83: 701, 1991) heart failure, proliferation of vascular smooth muscle cells, (Takagi, Biochem & Biophys. Res. Commun.; 168: 537-543, 1990, Bobek et al., Am. J. Physiol. 258:408-C415, 1990) and atherosclerosis, (Nakaki et al., Biochem. & Biophys. Res. Commun. 158: 880-881, 1989, and Lerman etal., New Eng. J. of Med. 325: 997-1001, 1991). Increased levels of endothelin have been shown after coronary balloon angioplasty (Kadel et al., No. 2491 Circ. 82: 627, 1990).
Further, endothelin has been found to be a potent constrictor of isolated mammalian airway tissue including human bronchus (Uchida et al., Eur J. of Pharm. 154: 227-228 1988, LaGente, Clin. Exp. Allergy 20: 343-348, 1990; and Springall et al., Lancet, 337: 697-701, 1991). Endothelin may play a role in the pathogenesis of interstitial pulmonary fibrosis and associated pulmonary hypertension, Glard et al., Third International Conference on Endothelin, 1993, p. 3.sup.4 and ARDS (Adult Respiratory Distress Syndrome), Sanai et al., Supra, p. 112.
Endothelin has been associated with the induction of hemorrhagic and necrotic damage in the gastric mucosa (Whittle et al., Br. J. Pharm. 95: 1011-1013, 1988); Raynaud's phenomenon, Cinniniello et al., Lancet 337: 114-115, 1991); Crohn's Disease and ulcerative colitis, Munch et al., Lancet, Vol. 339, p. 381; Migraine (Edme

REFERENCES:
patent: 3311628 (1967-03-01), Partyka et al.
patent: 3382245 (1968-05-01), Hansen et al.
patent: 4229453 (1980-10-01), Roth et al.
patent: 4918075 (1990-04-01), Zahler et al.
patent: 5098905 (1992-03-01), Malone et al.
patent: 5244896 (1993-09-01), Borcherding et al.
patent: 5248775 (1993-09-01), Taylor et al.
patent: 5254687 (1993-10-01), Taylor et al.
patent: 5281708 (1994-01-01), Josyula et al.
patent: 5328910 (1994-07-01), Hargreaves
patent: 5349064 (1994-09-01), Akimoto et al.
patent: 5378700 (1995-01-01), Sakuma et al.
patent: 5543413 (1996-08-01), Townsend et al.
patent: 5650511 (1997-07-01), Elliott et al.
Duffy et al., J. Chem. Soc., Perkins Transactions I, pp. 1921-1929, Oct. 1974.
Klumpp, Chemical Abstracts 111:19945, 1989.
Daly, Chemical Abstracts 109:221932, 1988.
Fokers, Chemical Abstracts 106:43451, 1986.
Steinhilber, Chemical Abstracts 106:27368, 1986.
Folkers, Chemical Abstracts 104:141712, 1985.
Dave et al., J. Indian Chem. Soc. vol. LXIV, No. 11, pp. 713-715, Nov. 1987. 4-Pyrimidylhydrazones, a 2-Bis(methylthio)methyleneaminopyrrole-3-carbonitrile, and a (1974).

Affiliated with

Also associated with

Rating

Endothelin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Endothelin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Endothelin receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1516987